Basic Information
| LncRNA/CircRNA Name | AGAP2-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:57726271-57728356 |
| Ensemble | ENSG00000255737 |
| Refseq | NR_027032 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | gemcitabine | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, RIP, Luciferase reporter assay etc |
| Sample | CRC tissues,CRC cell lines (DLD-1, SW480, HT29, CaCO2, RKO, HCT8) |
| Expression Pattern | up-regulated |
| Function Description | The expression of AGAP2-AS1 was overexpressed in CRC tissues and negatively correlated with the survival of patients with CRC. AGAP2-AS1 promoted CRC cell proliferation and inhibited apoptosis. Moreover, AGAP2-AS1 enhanced the chemoresistance of CRC cells to gemcitabine. In addition, AGAP2-AS1 enhanced the migration and invasion of CRC cells. Mechanistic studies showed that AGAP2-AS1 regulated fibroblast growth factor receptor 1 (FGFR1) expression by sponging miR-497 in CRC progression. |
| Pubmed ID | 32202509 |
| Year | 2020 |
| Title | LncRNA AGAP2-AS1 Augments Cell Viability and Mobility, and Confers Gemcitabine Resistance by Inhibiting miR-497 in Colorectal Cancer |
External Links
| Links for AGAP2-AS1 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |